If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Five year distribution agreement

4 Jan 2010 07:00

RNS Number : 9261E
Immunodiagnostic Systems Hldgs PLC
04 January 2010
 



Immunodiagnostic Systems Holdings plc

Five year distribution agreement

 

Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of diagnostic testing kits for the clinical and research markets, announces that Technogenetics s.r.l. ("Technogenetics") of Milan, Italy has signed a five year distribution agreement with A. Menarini Diagnostics ("Menarini") covering Europe for an automated test system, the Zenit RA, together with a panel of 21 tests for the diagnosis of autoimmune diseases. The Zenit RA is an OEM version of the IDS-iSYS system.

On 5 October 2009 IDS announced that it had signed an OEM manufacturing and supply agreement with Technogenetics, a subsidiary of Bouty S.p.A, the clinical diagnostics company (see RNS Reach number 1950A). As part of this agreement IDS will supply IDS-iSYS systems and consumables to Technogenetics on an OEM basis. These systems, branded as the Zenit RA, and consumables will be sold by Menarini as 'closed system' instruments throughout the whole of Europe and countries of the former Soviet Union such as Russia and Ukraine. Menarini is a leading company in the diagnostic field, with 14 direct subsidiaries, 1,000 employees and a consolidated turnover of 320 million Euros.

Commenting on the distribution agreement, Lorenzo Castellini, President of the Bouty Group, said: "We expect that over the five years the distribution agreement with A. Menarini Diagnostics will generate approximately €12 million in revenues from sales of diagnostic kits manufactured by Technogenetics with additional income from sales of instruments and ancillary reagents supplied by IDS."

Roger Duggan, CEO of IDS, said: "We're very pleased to see that our collaboration with Technogenetics is about to bear fruit and the deal signed between Technogenetics and Menarini significantly expands the route to market for Technogenetics’ autoimmune products. This can only enhance future sales of IDS-manufactured instruments and ancillary reagents across Europe, a great ‘upside’ to our agreement with Technogenetics.”

 

Enquiries:

 

Immunodiagnostic Systems Holdings Plc

Tel: 0191 519 0660

David Evans, Chairman

 

Roger Duggan, CEO

 

 

 

Brewin Dolphin Investment Banking

Tel: 0845 213 4730

Andrew Emmott

Sean Wyndham-Quin

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

 

paul.mcmanus@walbrookpr.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRKKNDQBBKDODK
Date   Source Headline
10th Sep 20147:00 amRNSAcquisition of Dia.Metra S.r.l.
21st Aug 20147:00 amRNSChinese FDA clearance for the IDS-iSYS instrument
4th Aug 20145:59 pmRNSAGM Results
4th Aug 20147:00 amRNSAGM Statement
30th Jul 201410:25 amRNSAdditional Listing
14th Jul 201411:36 amRNS2014 Annual Report & Accounts and Notice of AGM
24th Jun 20147:00 amRNSFinal Results
12th May 201410:51 amRNSHolding(s) in Company
15th Apr 20147:00 amRNSTrading Statement
13th Mar 20144:40 pmRNSSecond Price Monitoring Extn
13th Mar 20144:35 pmRNSPrice Monitoring Extension
7th Mar 20147:00 amRNSDirectorate Change
15th Jan 20144:28 pmRNSHolding(s) in Company
9th Jan 20147:00 amRNSFDA clearance of Direct Renin assay on IDS-iSYS
8th Jan 201412:47 pmRNSAdditional Listing
19th Dec 20134:36 pmRNSAdditional Listing
12th Dec 20136:20 pmRNSHolding(s) in Company
12th Dec 20136:19 pmRNSHolding(s) in Company
27th Nov 20137:00 amRNSHalf Yearly Report
10th Oct 20137:00 amRNSTrading Statement
8th Oct 20134:29 pmRNSHolding(s) in Company
8th Oct 20134:26 pmRNSHolding(s) in Company
27th Sep 201312:40 pmRNSHolding(s) in Company
24th Sep 20131:15 pmRNSAdditional Listing
4th Sep 20137:00 amRNSHolding(s) in Company
28th Aug 201312:46 pmRNSAdditional Listing
31st Jul 201312:20 pmRNSAdditional Listing
29th Jul 20133:24 pmRNSHolding(s) in Company
26th Jul 20133:08 pmRNSResult of AGM
26th Jul 201312:00 pmRNSAGM Statement
2nd Jul 20139:41 amRNSDirector/PDMR Shareholding
28th Jun 20139:46 amRNSAdditional Listing
28th Jun 20139:00 amRNSAnnual Report and AGM
26th Jun 20137:00 amRNSAdditional Listing
24th Jun 20137:00 amRNSFDA clearance of 1,25-Dihydroxy Vitamin D assay
21st Jun 20137:00 amRNSImmunodiagnostic Systems streamlines Board
17th Jun 20137:00 amRNSFinal Results
10th May 20134:29 pmRNSHolding(s) in Company
9th May 20133:22 pmRNSAdditional Listing
2nd May 20137:41 amRNSEntry into Chinese Diagnostics Market
25th Apr 20134:17 pmRNSTrading Update - Replacement
23rd Apr 20139:45 amRNSHolding(s) in Company
16th Apr 20135:03 pmRNSHolding(s) in Company
16th Apr 201311:42 amRNSHolding(s) in Company
10th Apr 20137:00 amRNSDistribution Agreement
10th Apr 20137:00 amRNSTrading Statement
5th Apr 201310:22 amRNSDirector/PDMR Shareholding
4th Apr 20134:43 pmRNSHolding(s) in Company
11th Feb 20137:00 amRNSCollaboration with Diagnostica Stago
14th Dec 20122:28 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.